+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Artemisinin Combination Therapy Market by Active Ingredient (Artemether Lumefantrine, Artesunate Amodiaquine, Artesunate Sulfadoxine Pyrimethamine), Dosage Form (Injectable, Oral Suspension, Tablet), End User, Distribution Channel, Patient Group - Global Forecast 2025-2030- Product Image
Artemisinin Combination Therapy Market by Active Ingredient (Artemether Lumefantrine, Artesunate Amodiaquine, Artesunate Sulfadoxine Pyrimethamine), Dosage Form (Injectable, Oral Suspension, Tablet), End User, Distribution Channel, Patient Group - Global Forecast 2025-2030- Product Image
Sale

Artemisinin Combination Therapy Market by Active Ingredient (Artemether Lumefantrine, Artesunate Amodiaquine, Artesunate Sulfadoxine Pyrimethamine), Dosage Form (Injectable, Oral Suspension, Tablet), End User, Distribution Channel, Patient Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013910
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Artemisinin Combination Therapy Market continues to transform global malaria treatment strategies, driven by evolving protocols, innovative formulations, and growing demands for effective supply chain resilience. Senior leaders in pharmaceuticals and healthcare procurement will find this report a data-rich resource for optimizing commercial and operational outcomes in a rapidly adapting landscape.

Market Snapshot: Artemisinin Combination Therapy Market Size and Growth

The Artemisinin Combination Therapy (ACT) Market grew from USD 362.34 million in 2024 to USD 386.40 million in 2025. It is projected to expand further at a CAGR of 6.52%, reaching USD 529.39 million by 2030. As the therapeutic gold standard in malaria treatment, ACT has become integral to national and international health programs, reflecting high adoption rates across regions with significant disease burden. Strategic investments, evolving clinical protocols, and robust manufacturing capabilities fuel sustained growth, highlighting this segment’s central role within the infectious disease pharmaceutical sector.

Scope & Segmentation

  • Active Ingredient: Artemether Lumefantrine, Artesunate Amodiaquine, Artesunate Sulfadoxine Pyrimethamine, Dihydroartemisinin Piperaquine
  • Dosage Form: Intramuscular injectable, Intravenous injectable, Granule sachet oral suspension, Syrup oral suspension, Co-packaged tablet, Fixed-dose combination tablet
  • End User: Private clinics, Public clinics, Private hospitals, Public hospitals, Caregiver-assisted homecare, Self administration at home
  • Distribution Channel: Hospital pharmacies, Online pharmacies, Retail pharmacies
  • Patient Group: Adult, Geriatric, Pediatric
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Players: Novartis AG, Sanofi SA, Cipla Limited, Viatris, Inc., Ipca Laboratories Ltd., Kunming Pharmaceutical Corp., Guilin Pharmaceutical Co., Ltd., Shin Poong Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd.

Key Takeaways

  • Shifts in treatment guidelines are encouraging the uptake of next-generation formulation options tailored to resistance profiles and population needs.
  • Manufacturing expansion in Asia and Africa is helping stabilize costs and reduce supply disruptions, reflecting strong alignment with evolving international standards.
  • Fixed-dose combinations and streamlined oral suspensions are enhancing adherence and facilitating broader access, particularly among pediatric and outpatient demographics.
  • Digital platforms are playing a growing role in improving patient education, supporting adherence monitoring, and strengthening real-time pharmacovigilance efforts.
  • Segmentation by patient group and end-user channel enables targeted outreach, ensuring that protocols match the varying demands of adults, children, and geriatric populations.
  • Collaborative R&D and licensing agreements between innovators and generics manufacturers are accelerating time-to-market for updated therapeutic options.

Tariff Impact: 2025 US Policy Repercussions

The introduction of new United States tariffs in 2025 triggered significant realignments across Artemisinin Combination Therapy supply chains. Manufacturers responded by diversifying their sourcing networks and advancing partnerships in untaxed markets. Strategic inventory planning and long-term contracting have emerged as preferred risk mitigation tactics. In parallel, health systems and distributors in endemic countries are refining procurement schedules to balance cost shifts, while advocacy groups pursue regulatory relief to sustain supply continuity. Overall, the tariff environment has put added emphasis on supplier flexibility and adaptive procurement practices.

Methodology & Data Sources

This report leverages a mixed-methods approach, integrating in-depth interviews with key market stakeholders, secondary analysis of peer-reviewed literature, regulatory filings, and extensive quantitative data from anonymized sales and production records. Cross-validation and follow-up with original data sources enhance credibility. Ethical standards, including informed consent and data privacy, were strictly observed.

Why This Report Matters

  • Enables actionable decision-making by revealing detailed market segmentation and evolving regulatory dynamics for Artemisinin Combination Therapy.
  • Supports procurement leaders and strategy executives in risk assessment, supply chain optimization, and portfolio planning across multiple regions and technologies.
  • Equips organizations to benchmark against leading players and adopt best practices for patient-centric, digitally enhanced treatment delivery.

Conclusion

The Artemisinin Combination Therapy Market stands at a pivotal juncture, with innovation, policy, and operational excellence shaping future growth. Strategic insights from this analysis provide a foundation for sustainable health outcomes and commercial leadership in global malaria control efforts.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising prevalence of pfkelch13 mutations undermining artemisinin combination therapy efficacy in Southeast Asia
5.2. Increased adoption of digital supply chain tracking to prevent stockouts of ACT in rural sub Saharan clinics
5.3. Development of single dose radical cure regimens combining ACTs with next generation primaquine prodrugs
5.4. Strategic partnerships between governments and NGOs to subsidize artemisinin combination therapies in low income countries
5.5. Rising demand for pediatric dispersible artemether lumefantrine formulations driven by high child malaria incidence rates
5.6. Integration of rapid diagnostic testing with mobile health platforms to optimize ACT prescription in remote communities
5.7. Shift in funding from global donors to domestic budgets impacting affordability and availability of ACT treatments
5.8. Emergence of triple combination therapies pairing artemisinin derivatives with novel partner drugs to combat resistance
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Artemisinin Combination Therapy Market, by Active Ingredient
8.1. Introduction
8.2. Artemether Lumefantrine
8.3. Artesunate Amodiaquine
8.4. Artesunate Sulfadoxine Pyrimethamine
8.5. Dihydroartemisinin Piperaquine
9. Artemisinin Combination Therapy Market, by Dosage Form
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Oral Suspension
9.3.1. Granule Sachet
9.3.2. Syrup
9.4. Tablet
9.4.1. Co Packaged
9.4.2. Fixed Dose Combination
10. Artemisinin Combination Therapy Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Private
10.2.2. Public
10.3. Homecare
10.3.1. Caregiver Assisted
10.3.2. Self Administration
10.4. Hospitals
10.4.1. Private
10.4.2. Public
11. Artemisinin Combination Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Artemisinin Combination Therapy Market, by Patient Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Artemisinin Combination Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Artemisinin Combination Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Artemisinin Combination Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Sanofi SA
16.3.3. Cipla Limited
16.3.4. Viatris, Inc.
16.3.5. Ipca Laboratories Ltd.
16.3.6. Kunming Pharmaceutical Corp.
16.3.7. Guilin Pharmaceutical Co., Ltd.
16.3.8. Shin Poong Pharmaceutical Co., Ltd.
16.3.9. Qilu Pharmaceutical Co., Ltd.
16.3.10. Sun Pharmaceutical Industries Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ARTEMISININ COMBINATION THERAPY MARKET: RESEARCHAI
FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. ARTEMISININ COMBINATION THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. ARTEMISININ COMBINATION THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE SULFADOXINE PYRIMETHAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GRANULE SACHET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CO PACKAGED, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PRIVATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PUBLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 135. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 136. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 137. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 138. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 139. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 140. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 141. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 142. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 143. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 144. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 145. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 148. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 149. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 150. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 151. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 152. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 153. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 156. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 269. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 270. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 271. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 275. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 276. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 277. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 278. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 279. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2018-2024 (USD MILLION)
TABLE 284. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOMECARE, 2025-2030 (USD MILLION)
TABLE 285. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
TABLE 290. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT GROUP, 2025-2030 (USD MILLION)
TABLE 291. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
TABLE 292. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2030 (USD MILLION)
TABLE 293. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 294. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 295. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 296. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 297. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2018-2024 (USD MILLION)
TABLE 298. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ORAL SUSPENSION, 2025-2030 (USD MILLION)
TABLE 299. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 300. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 301. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Artemisinin Combination Therapy market report include:
  • Novartis AG
  • Sanofi SA
  • Cipla Limited
  • Viatris, Inc.
  • Ipca Laboratories Ltd.
  • Kunming Pharmaceutical Corp.
  • Guilin Pharmaceutical Co., Ltd.
  • Shin Poong Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 386.4 Million
Forecasted Market Value ( USD ) by 2030 $ 529.39 Million
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antimalarial Drugs Market by Drug Class (Artemisinin Based Combination Therapy, Non Artemisinin Therapies), Route Of Administration (Injectable, Oral), Formulation, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Antimalarial Drugs Market by Drug Class (Artemisinin Based Combination Therapy, Non Artemisinin Therapies), Route Of Administration (Injectable, Oral), Formulation, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030 - Product Image

Artemisinin Combination Therapy Market Size, Share and Trends Analysis Report by Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Artemisinin Combination Therapy - Global Strategic Business Report - Product Image

Artemisinin Combination Therapy - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Artemisinin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Artemisinin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 75 Pages
  • Global
From
Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Artemisinin (CAS 63968-64-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From

About the Market

Artemisinin is a drug used to treat a variety of infectious diseases, including malaria, schistosomiasis, and filariasis. It is derived from the plant Artemisia annua, and is used in combination with other drugs to increase its effectiveness. Artemisinin is a potent antimalarial drug, and is the most effective treatment for malaria. It is also used to treat other parasitic infections, such as schistosomiasis and filariasis. Artemisinin is available in a variety of forms, including tablets, capsules, and injections. It is also available in combination with other drugs, such as mefloquine, piperaquine, and doxycycline. The drug is generally well tolerated, with few side effects. The Artemisinin market is highly competitive, with many companies offering the drug in various forms. Some of the companies in the market include Novartis, Sanofi, GlaxoSmithKline, Cipla, and Ranbaxy. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.